CLAIMS

1. A salt-based antifungal powder formulation comprising a sodium salt at a concentration of 5% w/w, L-leucine at a concentration of 30% w/w and an active agent, based on the total weight of the salt-based antifungal powder formulation, wherein the active agent is an antifungal agent.

2. The salt-based antifungal powder formulation according to claim 1, wherein the sodium salt is selected from the group consisting of sodium sulfate, sodium acetate, sodium bicarbonate, sodium butyrate, sodium chloride and sodium metabisulfite.

3. The salt-based antifungal powder formulation according to claim 2, wherein the sodium salt is sodium sulfate.

4. The salt-based antifungal powder formulation according to any one of claims 1 to 3, wherein the antifungal agent is selected from the group consisting of Fluconazole, Itraconazole and Voriconazole.

5. The salt-based antifungal powder formulation according to claim 4, wherein the antifungal agent is Fluconazole.

6. The salt-based antifungal powder formulation according to claim 4, wherein the antifungal agent is Itraconazole.

7. The salt-based antifungal powder formulation according to claim 4, wherein the antifungal agent is Voriconazole.

8. A delivery system comprising an inhaler and a salt-based antifungal powder formulation according to claim 1.